Tissue engineering. Part B, Reviews · 2025
Trigger Point Injection: A Therapeutic Propellant for Myofascial Pain Syndromes.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yi, Luo Peng, Chen Ping, Luo Guochen, Wu Fujun, Wang Chong, Li Jin, Zhang Yi, Wang Xin
Аннотация
Myofascial pain syndromes, stemming from trigger points within the muscles, represent a prevalent cause of localized or generalized pain in clinical practice. They have a high incidence rate and currently lack specific curative methods. Trigger point injection therapy is the most popular clinical approach, focusing primarily on these trigger points. Injectable drugs like glucose, normal saline, local anesthetics, botulinum toxin type A, steroid preparations, and platelet-rich plasma are available for this purpose. This treatment is advantageous due to its low cost and minimally invasive nature, showing promising results in early clinical use. However, the lack of consensus on the optimal injectable substance presents a significant challenge in clinical practice. This article reviews the progress in clinical research on trigger point injection therapy and drug efficacy, along with precautions for drug administration in managing myofascial pain syndrome. It aims to offer fresh perspectives for future studies and establish a theoretical foundation for treating and caring for myofascial pain syndrome.